Harnessing biology and technology to develop new depression treatments — update from Harvard Review

January 9, 2020 – New research into the biology of depression, along with new and evolving technologies, provides the basis for developing the next generation of treatments for major depressive disorder (MDD), according to the special January/February issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer. “By…

Details

Persistent genital arousal disorder — PAIN Reports® presents update on rare neurological disorder

January 9, 2020 – Imagine living with unwanted sexual arousals, occurring unexpectedly and repeatedly, unrelated to any sexual desire or pleasure. That’s the situation for women with a rare and disabling condition called persistent genital arousal disorder (PGAD), according to a case series in PAIN Reports®, the official open-access journal of the International Association for…

Details

Integral molecular announces preclinical P2X7 antibody assets for autoimmune disorders

PHILADELPHIA – Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces lead monoclonal antibodies (MAbs) against P2X7, a structurally complex ion channel that is the target for autoimmune disorders including atopic dermatitis and glomerulonephritis. The panel of P2X7 antibodies is fully humanized and optimized, and ready to progress towards preclinical studies. The…

Details

Advancing neural stimulation: Pitt engineer designs a wireless, light-activated electrode

PITTSBURGH (Jan. 9, 2020) … Neural stimulation is a pioneering technology that can be used to recover function and improve the quality of life for individuals who suffer from brain injury or disease. It serves an integral role in modern neuroscience research and human neuroprosthetics, including advancements in prosthetic limbs and brain-computer interfaces. A challenge…

Details